Article
Pediatrics
Vasiliki Tzotzola, Loizos Petrikkos, Vassilios Papadakis, Georgia Mitropoulou, Charikleia Kelaidi, Efthymios Dimitriadis, Sophia Polychronopoulou
Summary: The study retrospectively analyzed 66 pediatric cases of Langerhans cell histiocytosis (LCH), showing a significant increase in survival rates over time, with a reactivation rate of 18.2% and no common occurrence of late neurodegeneration. The prognostic value of single system disease status was confirmed to have a good outcome.
Article
Hematology
Joshua A. Fein, Roni Shouval, Jacques-Emmanuel Galimard, Myriam Labopin, Gerard Socie, Juergen Finke, Jan J. Cornelissen, Ram Malladi, Maija Itala-Remes, Patrice Chevallier, Kim H. Orchard, Donald Bunjes, Mahmoud Aljurf, Marie Therese Rubio, Jurjen Versluis, Mohamad Mohty, Arnon Nagler
Summary: Older age and comorbidities are factors that influence the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. This study aimed to determine the impact of individual comorbidities and their cumulative burden on the risk of nonrelapse mortality (NRM) in patients receiving low-intensity regimens. The findings showed an association between cardiac comorbidity, psychiatric disease, and increased NRM risk.
Article
Hematology
Malvi Savani, Kwang W. Ahn, Yue Chen, Sairah Ahmed, Amanda F. Cashen, Mazyar Shadman, Dipenkumar Modi, Farhad Khimani, Corey S. Cutler, Jasmine Zain, Jonathan E. Brammer, Andrew R. Rezvani, Timothy S. Fenske, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Mehdi Hamadani
Summary: This study compared the outcomes of reduced-intensity/non-myeloablative conditioning (RIC/NMA) and myeloablative conditioning (MAC) regimens in T-cell non-Hodgkin lymphoma (T-NHL) patients undergoing allogeneic transplant (allo-HCT). The results showed no significant differences in overall survival, non-relapse mortality, risk of progression/relapse, and therapy failure between the two regimens.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Stefan O. Ciurea, Monzr M. Al Malki, Piyanuch Kongtim, Jun Zou, Fleur M. Aung, Gabriela Rondon, Julianne Chen, Michiko Taniguchi, Salman Otoukesh, Auayporn Nademanee, Stephen J. Forman, Richard Champlin, Ketevan Gendzekhadze, Kai Cao
Summary: DSAs are a major cause of engraftment failure in HaploSCT patients. Treatment with PE, rituximab, IVIg, and donor buffy coat is effective in promoting engraftment in patients with DSAs 20,000 MFI or below.
Article
Cell & Tissue Engineering
Irit Milman Krentsis, Ran Orgad, Yangxi Zheng, Esther Bachar Lustig, Chava Rosen, Elias Shezen, Sandeep Yadav, Bar Nathansohn Levi, Miri Assayag, Neville Berkman, Harry Karmouty Quintana, Einav Shoshan, Christa Blagdon, Yair Reisner
Summary: Transplantation of lung progenitor cells provides a potential approach for lung regeneration in patients with lung diseases. Our study demonstrates that by conditioning the recipient mice and co-infusing hematopoietic and lung progenitor cells from the same donor, successful engraftment without post-transplant immune suppression can be achieved.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Suguru Uemura, Daiichiro Hasegawa, Kenji Kishimoto, Tomoko Fujikawa, Sayaka Nakamura, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Kayo Ozaki, Yoshiyuki Kosaka
Summary: This study examined the association between conditioning intensity and height growth in pediatric patients who underwent allo-HSCT. The results showed significant differences in height SDS between MAC and RIC groups at 2 and 3 years after allo-HSCT. Multivariate logistic regression analysis indicated that MAC regimen was associated with an increased risk of short stature at 3 years after allo-HSCT.
Article
Oncology
Yuxin Wang, Yao Sun, Jing Xie, Jiangwei Hu, Na Liu, Jianlin Chen, Botao Li, Sanchun Lan, Jingwen Niu, Lei Wang, Zhuoqing Qiao, Yu Zhang, Jing Ren, Bin Zhang, Liren Qian, Yehui Tan, Liping Dou, Yuhang Li, Liangding Hu
Summary: A Dec-containing preconditioning regimen before allo-HSCT may improve outcomes in TP53-mutant MDS patients, but further exploration of the underlying mechanism is needed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Mette Jorgensen, Jens C. Norgaard, Emma E. Ilett, Ramtin Z. Marandi, Marc Noguera-Julian, Roger Paredes, Daniel D. Murray, Jens Lundgren, Cameron Ross MacPherson, Henrik Sengelov
Summary: This study examines the impact of allogeneic hematopoietic stem cell transplantation (aHSCT) on the taxonomic features and metabolic functions of gut bacteria in patients with malignant hematologic disorders. The results show that there is a decrease in bacterial diversity and metabolic functions post-transplant, especially in the myeloablative group.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Jinye Zhu, Qingya Wang, Hanyun Ren, Yujun Dong, Yue Yin, Qian Wang, Zeyin Liang, Wei Liu, Qingyun Wang, Bingjie Wang, Yuan Li
Summary: This study retrospectively analyzed the effect of low-dose DAC treatment in AML/MDS patients undergoing allogeneic hematopoietic stem cell transplantation. The results showed that patients receiving DAC treatment had a significantly lower incidence of grade II-IV acute GVHD. This study provides a new treatment strategy for improving the prognosis of AML/MDS patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Sakurako Suma, Yasuhisa Yokoyama, Haruka Momose, Kenichi Makishima, Yusuke Kiyoki, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba
Summary: Cord blood transplantation with a fixed dose of fludarabine may be a promising salvage therapy for graft failure, leading to successful hematopoietic recovery.
Article
Hematology
Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridi Levrat, Urs Schanz, Gayathri Nair, Marc Ansari, Patrick Simon, Jakob R. Passweg, Nathan Cantoni
Summary: Reversing the order of application of cyclophosphamide and busulfan in myeloablative conditioning for allo-HCT patients may lead to better outcomes. Short-term results show advantages of CyBu over BuCy in terms of liver toxicity, while long-term follow-up demonstrates lower non-relapse mortality and higher survival with CyBu compared to BuCy.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Yanling Sun, Jingwen Zhang, Bing Long, Xiangzhong Zhang, Ruijuan Wen, Yi He, Xudong LI
Summary: The study demonstrated that the CLAG-M regimen combined with BuCy as conditioning before allo-HSCT in relapsed/refractory AML patients resulted in a high rate of complete remission and overall survival, with certain specific factors identified as risk factors for LFS.
Article
Biochemistry & Molecular Biology
Liliana Montella, Margaret Ottaviano, Vittorio Riccio, Fernanda Picozzi, Gaetano Facchini, Luigi Insabato, Mario Giuliano, Giovannella Palmieri
Summary: Langerhans cell histiocytosis is a rare disease with variable clinical presentation, and recent advances in understanding the role of mitogen-activated protein kinase signaling have led to increased use of targeted treatments. Imatinib, a tyrosine kinase inhibitor, has shown potential efficacy in refractory LCH cases, with positive results in controlling the disease noted in clinical studies.
Article
Hematology
Andrea Biondi, Valentino Conter, Mammen Chandy, Primus Ewald, Marie Lucia de Martino Lee, Vivek S. Radhakrishnan, Wannaphorn Rotchanapanya, Patricia Scanlan, Owen Patrick Smith, Boubacar Togo, Peter Hokland
Summary: As hematologists, the best treatment for patients with blood diseases may vary due to differing opinions and constraints, as well as differences in patient presentation and understanding worldwide. Patients in developed countries often present early and have a better understanding of their disease, impacting treatment management and outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Hematology
Muna Qayed, Benjamin Watkins, Scott Gillespie, Brandi Bratrude, Kayla Betz, Sung W. Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C. Harris, David Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R. Schultz, Gregory A. Yanik, Edmund K. Waller, Amelia Langston, Leslie S. Kean, John T. Horan
Review
Immunology
Olle Ringden, Guido Moll, Britt Gustafsson, Behnam Sadeghi
Summary: This article summarizes the authors' more than 20 years of scientific experience in the clinical use of MSCs and DSCs in different clinical settings. MSCs and DSCs have significant effects on the immune system and coagulation, and show potential clinical efficacy in conditions such as acute GvHD, ARDS, and hemorrhages.
FRONTIERS IN IMMUNOLOGY
(2022)
Letter
Oncology
Wilson Y. K. Chan, Pamela P. W. Lee, Daniel K. L. Cheuk, Eva W. M. Yeung, Kenneth C. W. Wong, C. K. Li, Godfrey C. F. Chan, Wing Leung
PEDIATRIC BLOOD & CANCER
(2023)
Letter
Oncology
Anthony P. Y. Liu, Grace K. S. Lam, Wilson Y. K. Chan, Terry T. W. Chow, Jeanny Cheung, Sally C. Y. Wong, Wing Leung, Pamela P. W. Lee, Frankie W. T. Cheng, Godfrey C. F. Chan
PEDIATRIC BLOOD & CANCER
(2023)
Article
Multidisciplinary Sciences
Jaime S. Rosa Duque, Xiwei Wang, Daniel Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Xiaofeng Mu, Asmaa Hachim, Yanmei Zhang, Sau Man Chan, Sara Chaothai, Kelvin K. H. Kwan, Karl C. K. Chan, John K. C. Li, Leo L. H. Luk, Leo C. H. Tsang, Wilfred H. S. Wong, Cheuk Hei Cheang, Timothy K. Hung, Jennifer H. Y. Lam, Gilbert T. Chua, Winnie W. Y. Tso, Patrick Ip, Masashi Mori, Niloufar Kavian, Wing Hang Leung, Sophie Valkenburg, Malik Peiris, Wenwei Tu, Yu Lung Lau
Summary: This study compares the immunogenicity and reactogenicity of two widely available SARS-CoV-2 vaccines, BNT162b2 (an mRNA vaccine) and CoronaVac (a whole-virus inactivated vaccine), in healthy adolescents. The results show that the antibody and T cell immune responses in adolescents receiving two doses of either BNT162b2 or CoronaVac are similar to those seen in adults receiving two doses of the same vaccine. However, the immune response to a single dose of BNT162b2 in adolescents is not as robust. Additionally, CoronaVac induces a higher proportion of adolescents to have positive antibody responses compared to adults. Adverse reactions are generally mild for both vaccines, with BNT162b2 having slightly more frequent adverse reactions.
NATURE COMMUNICATIONS
(2022)
Article
Cell & Tissue Engineering
Behnam Sadeghi, Myrese Witkamp, Dominik Schefberger, Anna Arbman, Olle Ringden
Summary: Human placenta-derived decidua stromal cells (DSCs) have been used in clinical trials for the treatment of acute inflammatory diseases, but the mechanisms of action and interaction with other immune cells require further exploration.
Editorial Material
Hematology
Mary Eapen
Summary: This article reports on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and conservative management for adult patients with inborn errors of immunity (IEI).
Article
Oncology
Tianyi Wang, Yanjing Tang, Jiaoyang Cai, Xinyu Wan, Shaoyan Hu, Xiaoxi Lu, Zhiwei Xie, Xiaohong Qiao, Hui Jiang, Jingbo Shao, Fan Yang, Hong Ren, Qing Cao, Juan Qian, Jian Zhang, Kang An, Jianmin Wang, Chengjuan Luo, Huanhuan Liang, Yan Miao, Yani Ma, Xiang Wang, Lixia Ding, Lili Song, Hailong He, Wenhua Shi, Peifang Xiao, Xiaomin Yang, Jing Yang, Wenjie Li, Yiping Zhu, Ningling Wang, Longjun Gu, Qimin Chen, Jingyan Tang, Jun J. Yang, Cheng Cheng, Wing Leung, Jing Chen, Jun Lu, Benshang Li, Ching-Hon Pui
Summary: This study aimed to evaluate the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory or relapsed B-acute lymphoblastic leukemia. The results showed that 99.0% of patients with refractory leukemia or hematologic relapse achieved complete remission, and all patients were negative for minimal residual disease. Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. However, cytokine release syndrome and CAR T-cell neurotoxicity occurred in a minority of patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, Nancy L. DiFronzo, Erica B. Esrick, Joshua J. Field, Courtney D. Fitzhugh, Julie Kanter, Neena Kapoor, Donald B. Kohn, Lakshmanan Krishnamurti, Wendy B. London, Michael A. Pulsipher, Sohel Talib, Alexis A. Thompson, Edmund K. Waller, Ted Wun, Mary M. Horowitz
Summary: This study investigates the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. The results show that the 10-year incidence of leukemia/MDS was 1.7% and of any secondary neoplasm was 2.4%. Low-intensity regimens were associated with higher risks for leukemia/MDS or any secondary neoplasm compared with more intense regimens.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Mary Eapen, Ruta Brazaukas
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Robert Peter Gale, Wolfgang Hinterberger, Neal S. Young, Andrew R. Gennery, Christopher C. Dvorak, Kyle M. Hebert, Michael Heim, Larisa Broglie, Mary Eapen
Article
Hematology
Juan C. Fierro-Pineda, Hua-Ling Tsai, Amanda Blackford, Andrew Cluster, Emi Caywood, Jignesh Dalal, Jeffrey Davis, Maarten Egeler, Jeffrey Huo, Michelle Hudspeth, Amy Keating, Susan S. Kelly, Joerg Krueger, Dean Lee, Leslie Lehmann, Lisa Madden, Benjamin Oshrine, Michael A. Pulsipher, Terry Fry, Heather J. Symons
Summary: This study reports the results of a multicenter trial for pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndrome (MDS). The use of specific treatment strategies resulted in low transplant-related mortality and incidence of acute and chronic graft-versus-host disease (aGVHD and cGVHD). Patients had high overall survival rates and event-free survival rates.
Article
Hematology
Marta Verna, Marta Canesi, Valentino Conter, Lawrence Faulkner, Attilio Maria Rovelli, Daniela Silvestri, Ignazio Majolino, Andrea Biondi, Chra Nawfal Abdullah, Vian Faeq Mohammed
Summary: Thalassemia is a common and life-threatening disorder in children in regions prone to hemoglobinopathy, such as the Middle East. Hematopoietic stem cell transplantation (HSCT) is a highly effective and cost-effective treatment for thalassemia. A study in Iraqi Kurdistan demonstrated the successful establishment of an HSCT unit for both adults and children, achieving comparable results to international standards. The success of the program relied on meeting minimum requirements, international collaboration, and capacity-building efforts.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Alessandro Cattoni, Giulia Capitoli, Sara Casagranda, Paola Corti, Marta Adavastro, Alessandro Molinaro, Filiberto Di Gennaro, Sonia Bonanomi, Andrea Biondi, Stefania Galimberti, Adriana Balduzzi
Summary: This retrospective study aimed to assess the prevalence, severity, risk factors, and management of iron overload (IOL) in pediatric patients who underwent hematopoietic stem cell transplantation (HSCT). The results showed that 73% of patients had some degree of IOL, with a higher severity observed in patients with malignant diseases. Pre-HSCT and maximum post-HSCT ferritin levels were statistically higher in patients with malignancies, and radiologic assessment confirmed a more severe degree of IOL in these patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)